Predict your next investment

Venture Capital
solasta-ventures.com

See what CB Insights has to offer

Investments

13

Portfolio Exits

3

About Solasta Ventures

Solasta Ventures is the wholly-owned U.S. subsidiary of AJU IB Investment, a South Korean venture capital firm. It focuses on investing in healthcare and life sciences companies.

Solasta Ventures Headquarter Location

800 Boylston Street Suite 2510

Boston, Massachusetts, 02199,

United States

617-391-0403

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Solasta Ventures News

HotSpot Therapeutics Closes $65M Series B Financing

May 21, 2020

HotSpot Therapeutics , a Boston, MA-based biotechnology company advancing the discovery and development of first-in-class allosteric therapies targeting nature’s regulatory sites, closed a $65m Series B financing. The round was led by S.R. One, Limited and included funds managed by Tekla Capital Management, MRL Ventures Fund, Solasta Ventures and Brace Pharma (via affiliate Cleva Pharma), along with co-founding investors Atlas Venture and Sofinnova Partners. Concurrent with the financing, Jill Carroll, Partner at S.R. One, Limited, and Henry Skinner, PhD, Senior Vice President, Venture at Tekla Capital Management have joined the HotSpot Board of Directors. The company intends to use the funds to advance its lead programs to the clinic, including protein kinase C (PKC-theta) antagonists for Th2 and T-reg driven autoimmune disease and S6 kinase (S6K) antagonists for rare metabolic disease, and accelerate the discovery-stage pipeline targeting genetically validated transcription factors and E3 ligases, including CBL-B. Led by Jonathan Montagu, CEO, HotSpot Therapeutics is creating allosteric medicines that exploit natural control mechanisms. Leveraging understanding of protein structure-function, the SpotFinder™ platform identifies critical regulatory regions on proteins – “regulatory hotspots” – that are amenable to small molecule drug discovery. The platform uses advanced machine learning techniques to discover the underlying fingerprints of regulatory pockets. Using 3D structure insights from the uncovered pockets, the company has designed in-house DNA-encoded libraries (DEL) that comprise millions of tailored molecules. A proprietary screening paradigm using custom protein constructs, phenotypic screens and biophysics assays is then used to demonstrate the differentiated properties of hotspot-targeted molecules. FinSMEs 21/05/2020

Solasta Ventures Investments

13 Investments

Solasta Ventures has made 13 investments. Their latest investment was in Trefoil Therapeutics as part of their Series A - III on March 3, 2022.

CBI Logo

Solasta Ventures Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

3/22/2022

Series A - III

Trefoil Therapeutics

$11.97M

Yes

1

2/14/2022

Series B - II

Soul Machines

$70M

Yes

10

11/23/2021

Series C - III

Rescale

$50M

No

5

8/18/2021

Series B

Subscribe to see more

$99M

Subscribe to see more

10

6/29/2021

Series C - II

Subscribe to see more

Subscribe to see more

10

Date

3/22/2022

2/14/2022

11/23/2021

8/18/2021

6/29/2021

Round

Series A - III

Series B - II

Series C - III

Series B

Series C - II

Company

Trefoil Therapeutics

Soul Machines

Rescale

Subscribe to see more

Subscribe to see more

Amount

$11.97M

$70M

$50M

$99M

New?

Yes

Yes

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

1

10

5

10

10

Solasta Ventures Portfolio Exits

3 Portfolio Exits

Solasta Ventures has 3 portfolio exits. Their latest portfolio exit was Arcellx on February 04, 2022.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

2/4/2022

IPO

9

10/22/2021

IPO

Subscribe to see more

Subscribe to see more

10

7/29/2021

IPO

Subscribe to see more

$99M

Subscribe to see more

10

Date

2/4/2022

10/22/2021

7/29/2021

Exit

IPO

IPO

IPO

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Sources

9

10

10

Solasta Ventures Team

1 Team Member

Solasta Ventures has 1 team member, including current Chief Executive Officer, President, Derek Yoon.

Name

Work History

Title

Status

Derek Yoon

Berwind Private Equity, and Kibo Technology Advancing Capital

Chief Executive Officer, President

Current

Name

Derek Yoon

Work History

Berwind Private Equity, and Kibo Technology Advancing Capital

Title

Chief Executive Officer, President

Status

Current

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.